Dashboard
1
Negative results in Mar 26
- NET PROFIT(HY) At CNY -132.54 MM has Grown at -174.93%
- ROCE(HY) Lowest at 4.25%
- INTEREST(Q) At CNY 19.16 MM has Grown at 57.37%
2
With ROE of -1.78%, it has a very expensive valuation with a 1.40 Price to Book Value
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,468 Million (Small Cap)
NA (Loss Making)
NA
0.75%
0.28
-1.78%
1.51
Revenue and Profits:
Net Sales:
1,049 Million
(Quarterly Results - Jun 2026)
Net Profit:
100 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.0%
0%
6.0%
6 Months
-10.21%
0%
-10.21%
1 Year
-26.75%
0%
-26.75%
2 Years
-26.09%
0%
-26.09%
3 Years
-31.4%
0%
-31.4%
4 Years
-31.08%
0%
-31.08%
5 Years
-58.35%
0%
-58.35%
Sirio Pharma Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.24%
EBIT Growth (5y)
-37.46%
EBIT to Interest (avg)
4.40
Debt to EBITDA (avg)
1.19
Net Debt to Equity (avg)
0.23
Sales to Capital Employed (avg)
1.06
Tax Ratio
100.00%
Dividend Payout Ratio
29.10%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.84%
ROE (avg)
10.53%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.66
EV to EBIT
199.99
EV to EBITDA
23.42
EV to Capital Employed
1.52
EV to Sales
1.33
PEG Ratio
NA
Dividend Yield
0.68%
ROCE (Latest)
0.76%
ROE (Latest)
-1.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
1,048.80
1,087.40
-3.55%
Operating Profit (PBDIT) excl Other Income
198.80
172.40
15.31%
Interest
25.90
24.60
5.28%
Exceptional Items
-1.20
-0.20
-500.00%
Consolidate Net Profit
100.50
79.80
25.94%
Operating Profit Margin (Excl OI)
121.20%
95.40%
2.58%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -3.55% vs 4.66% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 25.94% vs -2.68% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,250.40
4,195.60
1.31%
Operating Profit (PBDIT) excl Other Income
539.90
689.00
-21.64%
Interest
106.20
97.30
9.15%
Exceptional Items
-169.90
-21.90
-675.80%
Consolidate Net Profit
20.40
282.00
-92.77%
Operating Profit Margin (Excl OI)
59.90%
95.50%
-3.56%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 1.31% vs 17.47% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -92.77% vs 17.35% in Dec 2024
About Sirio Pharma Co., Ltd. 
Sirio Pharma Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






